## Makda S Gebre

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1686746/publications.pdf

Version: 2024-02-01

21 papers

5,296 citations

16 h-index 22 g-index

27 all docs

27 docs citations

times ranked

27

10250 citing authors

| #  | Article   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature, 2021, 590, 630-634.   | 13.7 | 995       |
| 2  | DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.  | 6.0  | 978       |
| 3  | SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.  | 6.0  | 789       |
| 4  | Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.  | 13.7 | 765       |
| 5  | Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.                    | 3.8  | 307       |
| 6  | Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nature Medicine, 2020, 26, 1694-1700.   | 15.2 | 275       |
| 7  | Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1535.                                      | 3.8  | 260       |
| 8  | Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination. New England Journal of Medicine, 2021, 385, 951-953.                        | 13.9 | 192       |
| 9  | Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.   | 13.5 | 145       |
| 10 | Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antiviral Research, 2017, 137, 14-22.          | 1.9  | 132       |
| 11 | Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nature Communications, 2021, 12, 1018.   | 5.8  | 82        |
| 12 | Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Journal of Virology, 2021, 95, .                    | 1.5  | 80        |
| 13 | Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. Nature, 2022, 601, 410-414.  | 13.7 | 71        |
| 14 | MYC Controls the Epstein-Barr Virus Lytic Switch. Molecular Cell, 2020, 78, 653-669.e8.   | 4.5  | 67        |
| 15 | Feasibility and safety of ultrasound-guided minimally invasive autopsy in COVID-19 patients. Abdominal Radiology, 2021, 46, 1263-1271.                            | 1.0  | 33        |
| 16 | CRISPR–Cas9 Genetic Analysis of Virus–Host Interactions. Viruses, 2018, 10, 55.   | 1.5  | 20        |
| 17 | Serum amyloid A (SAA) is an early biomarker of influenza virus disease in BALB/c, C57BL/2, Swiss-Webster, and DBA.2 mice. Antiviral Research, 2016, 133, 196-207. | 1.9  | 12        |
| 18 | Alpha-defensin 5 differentially modulates adenovirus vaccine vectors from different serotypes in vivo. PLoS Pathogens, 2019, 15, e1008180.                        | 2.1  | 10        |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | A Modular Biomaterial Scaffoldâ€Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS oVâ€2<br>Antigens. Advanced Healthcare Materials, 2021, 10, e2101370. | 3.9 | 10        |
| 20 | Strain-dependent disease and response to favipiravir treatment in mice infected with Chikungunya virus. Antiviral Research, 2020, 182, 104904.                        | 1.9 | 9         |
| 21 | Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. Npj Vaccines, 2022, 7, 23.                                       | 2.9 | 6         |